Holen Sie sich die Stockscreener-App
27.00
0.75%
0.20
Handel nachbörslich:
27.00
Schlusskurs vom Vortag:
$26.80
Offen:
$27.09
24-Stunden-Volumen:
465.51K
Relative Volume:
2.33
Marktkapitalisierung:
$1.69B
Einnahmen:
$286.00M
Nettoeinkommen (Verlust:
$305.47M
KGV:
-11.52
EPS:
-2.3434
Netto-Cashflow:
$-492.33M
1W Leistung:
-3.50%
1M Leistung:
-12.22%
6M Leistung:
-8.88%
1J Leistung:
-28.02%
1-Tages-Spanne:
$26.80
$27.54
1-Wochen-Bereich:
$26.73
$28.23
52-Wochen-Spanne:
$24.16
$42.45
Galapagos Nv Adr Stock (GLPG) Company Profile
Firmenname
Galapagos Nv Adr
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie GLPG mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| GLPG | 27.00 | 1.69B | 286.00M | 305.47M | -492.33M | -2.3434 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Galapagos Nv Adr Stock (GLPG) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-09-09 | Eingeleitet | Leerink Partners | Market Perform |
| 2024-08-02 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2024-03-28 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2024-03-07 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-08-24 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-05-05 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-01-23 | Hochstufung | Jefferies | Underperform → Hold |
| 2022-11-07 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2022-09-09 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-01-27 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-08-19 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2021-08-06 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2021-04-20 | Eingeleitet | Deutsche Bank | Buy |
| 2021-04-14 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2021-02-23 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2021-02-19 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2021-02-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-01-19 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-11-19 | Eingeleitet | Maxim Group | Buy |
| 2020-10-21 | Herabstufung | Goldman | Neutral → Sell |
| 2020-08-25 | Herabstufung | Jefferies | Buy → Hold |
| 2020-08-24 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2020-08-19 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2020-08-19 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-07-10 | Herabstufung | Stifel | Buy → Hold |
| 2020-03-30 | Hochstufung | Jefferies | Hold → Buy |
| 2020-03-18 | Hochstufung | RBC Capital Mkts | Underperform → Sector Perform |
| 2020-02-25 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2020-02-24 | Herabstufung | BofA/Merrill | Neutral → Underperform |
| 2020-02-20 | Herabstufung | RBC Capital Mkts | Sector Perform → Underperform |
| 2020-01-06 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2019-12-18 | Herabstufung | Citigroup | Buy → Neutral |
| 2019-12-17 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2019-12-13 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2019-12-02 | Eingeleitet | BofA/Merrill | Neutral |
| 2019-09-09 | Fortgesetzt | Morgan Stanley | Overweight |
| 2019-07-31 | Hochstufung | UBS | Neutral → Buy |
| 2019-07-29 | Herabstufung | Jefferies | Buy → Hold |
Alle ansehen
Galapagos Nv Adr Aktie (GLPG) Neueste Nachrichten
Belgium shares higher at close of trade; BEL 20 up 0.58% - MSN
Deutsche Bank maintains Hold on Galapagos, reducing target with key updates months away - Investing.com
Earnings call: Galapagos reports solid Q3 progress, eyes IND studies By Investing.com - Investing.com South Africa
Earnings call: Galapagos reports solid Q3 progress, eyes IND studies - Investing.com
Galapagos stock outlook cautious with clinical readouts on the horizon, says Morgan Stanley - Investing.com
Galapagos ADR earnings missed by $0.05, revenue topped estimates - Investing.com UK
Galapagos receives transparency notification from EcoR1 Capital - GlobeNewswire Inc.
Leerink Partners gives Market Perform rating to Galapagos NV stock, flags R&D challenges - Investing.com
Navigating GLPG Stock: Galapagos NV ADR Journey - The InvestChronicle
Why MIRA Pharmaceuticals Shares Are Trading Higher By Around 45%; Here Are 20 Stocks Moving Premarket - Benzinga
Galapagos (GLPG) Up on FDA Nod to Begin Phase I/II Lymphoma Study - Yahoo Finance
Morgan Stanley cuts Galapagos NV target to $32 from $35 - Investing.com
Earnings call: Galapagos focuses on oncology and immunology in H1 2024 report - Investing.com
Belgium stocks higher at close of trade; BEL 20 up 1.37% - Investing.com
Treasuries slip, dollar firm as markets grapple with US politics By Reuters - Investing.com
Belgium stocks lower at close of trade; BEL 20 down 0.90% - Investing.com
Belgium stocks lower at close of trade; BEL 20 down 0.24% By Investing.com - Investing.com
Belgium stocks lower at close of trade; BEL 20 down 0.32% By Investing.com - Investing.com
Galapagos NV shares poised for outperformance, says TD Cowen - Investing.com India
Galapagos NV shares poised for outperformance, says TD Cowen By Investing.com - Investing.com
Belgium stocks lower at close of trade; BEL 20 down 0.79% By Investing.com - Investing.com
Belgium shares lower at close of trade; BEL 20 down 0.79% - Investing.com India
Belgium stocks higher at close of trade; BEL 20 up 1.28% By Investing.com - Investing.com
Belgium shares higher at close of trade; BEL 20 up 1.28% - Investing.com India
Belgium stocks lower at close of trade; BEL 20 down 0.40% By Investing.com - Investing.com
Belgium shares lower at close of trade; BEL 20 down 0.40% - Investing.com India
Adaptimmune and Galapagos partner on cancer therapy By Investing.com - Investing.com
Adaptimmune and Galapagos partner on cancer therapy - Investing.com India
Are Medical Stocks Lagging Galapagos (GLPG) This Year? - Yahoo Singapore News
Earnings call: Galapagos outlines strategic focus in Q1 2024 results By Investing.com - Investing.com
Citi lowers Galapagos NV shares target amid restructuring and pipeline investments By Investing.com - Investing.com
Allied Gaming & Entertainment insider buys shares worth over $456,000 By Investing.com - Investing.com
Morgan Stanley sets Galapagos stock at equalweight, $38 price target By Investing.com - Investing.com
Merck's (MRK) Chronic Cough Drug Gets Another CRL From FDA - Yahoo Finance
Morgan Stanley lists biotechs with negative enterprise value, 2022 catalysts (NASDAQ:GLPG) - Seeking Alpha
Galapagos Surges On New CEO and Upgrade News - Investing.com
Galapagos: Market Values Pipeline Below $0 (NASDAQ:GLPG) - Seeking Alpha
The Week Ahead In Biotech: Spotlight On Gilead, BioMarin FDA Decisions, IPOs - Yahoo Finance
The Daily Biotech Pulse: Novo Nordisk's Ozempic Receives Label Expansion For Cardiovascular Events, Adcom Disappointment Inflicts Pain On Durect Shares - Yahoo Finance
The Daily Biotech Pulse: Osmotica Soars On Insider Buys, Ultragenyx's Partnered Rare Disease Drug Moves I - Benzinga
The Daily Biotech Pulse: Nektar Withdraws Opioid Pain Drug NDA, Galapagos Takes Stake In Fibrocor, Integr - Benzinga
Is Galapagos NV (GLPG) A Good Stock To Buy? - Insider Monkey
The Daily Biotech Pulse: ASH Meeting Wraps, Fast Track Designation For Equillium, Pfizer To Buy $3M In ContraFect Shares - Yahoo Finance
The Daily Biotech Pulse: Cassava Gains On Alzheimer's Presentation, Bristol-Myers Hikes DividendAlecto - Benzinga
World’s Top-Selling Drugs: Gilead Sciences, Inc. Sovaldi Closes In On AbbVie Inc Humira - Crypto Coins Tribune
The Daily Biotech Pulse: FDA Nod For STAAR, Supernus Opens Wallet, Principia Biopharma To DebutStaar S - Benzinga
The Week Ahead In Biotech: Conferences, Clinical Trial Results, Earnings And IPOsAmarin Corp (NASDAQ:A - Benzinga
AIM tech shares that broke America - Interactive Investor
25 Stocks Moving In Friday's Pre-Market SessionAlnylam Pharmaceuticals (NASDAQ:ALNY), Aclaris Therapeu - Benzinga
Why Vertex Pharmaceuticals Incorporated (VRTX) Stock Isn't Worth the Risk - InvestorPlace
25 Stocks Moving In Thursday's Pre-Market SessionAegon (NYSE:AEG) - Benzinga
Finanzdaten der Galapagos Nv Adr-Aktie (GLPG)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.66%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):